Carboplatin in pediatric oncology;Le carboplatine en pediatrie

Bulletin du Cancer

Volumn 87, Issue SPEC. ISS. AUG., 2000, Pages 25-29

  Doz, F ^a  

^a INSTITUT CURIE   (France)

Author keywords

Carboplatin; Children

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

AREA UNDER THE CURVE; BLOOD TOXICITY; CHILDHOOD CANCER; DRUG EFFICACY; HUMAN; MUTAGENESIS; REVIEW; SOLID TUMOR; CHILD; DRUG EFFECT; GLOMERULUS; METABOLISM; NEUROBLASTOMA; RETINOBLASTOMA; THROMBOCYTE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; CARBOPLATIN; CHILD; CISPLATIN; HUMANS; KIDNEY GLOMERULUS; NEUROBLASTOMA; RADIATION-SENSITIZING AGENTS; RETINOBLASTOMA;

EID: 0033817112     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Phase I study of carboplatin (CBDCA) in children with cancer
2. 2 in children
3. The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer
4. Clinical pharmacokinetics of carboplatin in children
5. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
6. Carboplatin pharmacokinetics in children: The development of a pediatric dosage formula. The United Kingdom children's cancer study Group
7. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients
8. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children
9. Population pharmacokinetics of carboplatin in children
10. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin
11. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma
12. Multi-organ dysfunction associated with high-dose carboplatin therapy prior to autologous transplantation
13. Nephrotoxicity following carboplatin use in children: Is routine monitoring of renal function necessary?
14. Acute and cumulative effects of carboplatin on renal function
15. Carboplatin and renal function in children
16. Carboplatin is ototoxic
17. Severe otoroxicity following carboplatin-containing conditioning regimen for autologcus marrow transplantation for neuroblastoma
18. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue
19. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood
20. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas
21. Carboplatin hypersensitivity in children: A report of five patients with brain tumors
22. Hypersensitivity to carboplatin in children
23. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions
24. Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminedichloro-platinum-II-based regimen for osteosarcoma
25. Acute promyelocytic leukaemia after treatment for seminoma with carboplatin
26. Effects of carboplatin on the testis: A histological study
27. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastin, and bleomycin versus surveillance
28. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors: A multi-institutional study
29. What is the place of carboplatin in paediatric oncology ?
30. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
31. Carboplatin activity in cisplatin treated neuroblastoma
32. Carboplatin and recurrent childhood brain tumors
33. Treatment of children with progressive or recurrent brain tumors with Carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study
34. Carboplatin in childhood brain tumors: A Children's Cancer Study Group phase II trial
35. Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors
36. Carboplatin pharmacokinetics in young children with brain tumors
37. Carboplatin in childhood medulloblastoma/PNET: Feasibility of an in vivo sensitivity test in an << up-front >> study
38. Phase II study of carboplatin as a single drug for relapsed Wilm's tumor: Experience of the Brazilian Wilm's Tumor Study Group
39. Response of untreated stage IV Wilm's tumor to single dose carboplain assessed by << up front >> window therapy
40. Activity of intraarterial carboplarin as a single agent in the treatment of newly diagnosed extremity osteosarcoma
41. Etoposide and carboplatin in neuroblastoma: A French Society of Pediatric Oncology phase II study
42. The treatment of neuroblastoma with intrasplnal extension with chemotherapy followed by surgical removal of residual disease
43. Unresectable localized neuroblastoma: Improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastome Study Group of the Sociere francaise d'oncologie pediatrique (SFOP)
44. High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors
45. Etoposide and carboplatin: A highly effective combination in relapsed or refractory Wilm's tumor - A phase II study by the French Society of Pediatric Oncology
46. Etoposide and carboplatine in extraocular retinoblastoma: A study by the Societe francaise d'oncologie pediatrique
47. UKCCSG'S Germ Cell Tumour (GC'T) studies: Improving outcome for children with malignant extracranial non-gonadal tumours - Carboplatin, etoposide, and bleomycin are effective and less toxic than previous regimens
48. The use of ifosfamide, carboplatin and etoposide in children with solid tumors
49. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid rumors
50. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors
51. Response of pediatric malignant solid rumors following ifosfamide or ifosfamide/carboplatin/etoposide: A single hospital experience
52. Treatment of diencephalic syndrome with chemotherapy
53. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with meastatic nasopharyngeal carcinoma
54. Phase II study of cisplatinum and carboplatinum (CACIS) combination in advanced stage neuroblastomas
55. A phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow: A report of the Children's Cancer Group
56. A phase II dinical trial of carboplatin infusion of high-risk acute nonlymphoblastic leukemia
57. Phase II clinical trial of carboplatin in relapsed and refractory leukemia
58. Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity?
59. Escalating sequential high-dose carboplatin and eoposide with autologous marrow support in children with relapsed solid tumors
60. Toxicity of single-day high-dose vincrisrine, melphalan, eroposide and carboplatin with autologous bone marrow rescue in advanced neuroblastoma
61. 2): A report from the LMCE group
62. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol
63. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors
64. High-dose melphalan, etoposide et carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilm's tumor: A French Society of Pediatric Oncology Study
65. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: A SFOP and SFGM study
66. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensity therapy
67. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: A phase I/II study
68. Chemotherapy plus local treatment in the management of intraocular retinoblastoma
69. Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: Preliminary results